Severe acute respiratory syndrome

Yocova: Rehiring and retraining cockpit and cabin crews. This time it's personnel!

Retrieved on: 
Thursday, August 5, 2021
Love, Work, Chief executive officer, International Air Transport Association, Association, Data collection, Solidarity, ANSP, Industry, Retirement, RAA, Aircraft, Mint, Community, Severe acute respiratory syndrome, Boeing, Original equipment manufacturer, Regional Airline Association, Airport, MPL, Time, SCCM, De Montfort University, FTD, Growth, COVID-19, Revenue stream, Workforce, Education, DWP, Department, First officer (aviation), Mentorship, Aviation, Rolls-Royce, Quarantine, LPC, Whyte, Income, Ecosystem, Safety, Head, Emotion, Mirjam Orsel, Airline, Tourism, Online shopping, Management, Sales

On the human side, the pandemic brought huge numbers of pilot and cabin crew furloughs and redundancies which were incredibly painful for many of those affected.

Key Points: 
  • On the human side, the pandemic brought huge numbers of pilot and cabin crew furloughs and redundancies which were incredibly painful for many of those affected.
  • "For those crews flying on small regional jets and turboprops, the future looks brighter than for the pilots and cabin crew on medium and heavy jets.
  • Resilient Pilot is a company celebrating its first anniversary after being created in direct response to the pandemic and launched in May 2020.
  • One of the key elements of bringing crew back online is the actual process of call backs and rehiring.

CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest

Retrieved on: 
Thursday, August 5, 2021
Infectious Diseases, Biotechnology, AIDS, Health, Optimism, Patent, Severe acute respiratory syndrome, Suite, Social conditioning, Beneficial ownership, Board, Annual general meeting, Clinical trial, District court, Annual report, District, OTC Markets Group, Refusal, HIV, Lavender Hill Mob (gay activist group), Biologics license application, Food and Drug Administration, Nash, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Chief executive officer, Vaccine, THE, Partnership, File, Viral load, SEC, Activism, Form 10-K, Compliance, Food, Company, U.S. Securities and Exchange Commission, United States Patent and Trademark Office, Name, Risk, Patient, Main Street, COVID-19, BLA, CCR5, Forward-looking statement, Animal, Management, Pharmaceutical industry

The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control of the Companys Board of Directors (the Board).

Key Points: 
  • The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control of the Companys Board of Directors (the Board).
  • The Activist Group has since then stated that it intends to press on with its proxy contest and has continued with its efforts to make misrepresentations to shareholders.
  • We believe the Rosenbaum/Patterson Group has been purposely misleading shareholders and, in the process, has violated securities laws.
  • In its complaint, the Company details a number of misleading statements of the activities of the Rosenbaum/Patterson Group.

MACE Virtual Labs Partners With Uvisan to Create Safer, More Hygienic VR and AR Programs

Retrieved on: 
Thursday, August 5, 2021
Virtual Labs, Tablet, Solution, International Organization for Standardization, Organization, Technology, List of International Electrotechnical Commission standards, Severe acute respiratory syndrome, Mace, Partnership, Coronavirus, VR, HMDS, Disinfectant, AR, COVID-19, Cleanroom, Private sector, Eye, IEC, XR, Education, Video game console, Online shopping

HOUSTON, Aug 5, 2021 /PRNewswire/ -- MACE Virtual Labs , a turnkey provider of virtual and augmented reality programs, has partnered with Uvisan , a leader in rapid equipment disinfection.

Key Points: 
  • HOUSTON, Aug 5, 2021 /PRNewswire/ -- MACE Virtual Labs , a turnkey provider of virtual and augmented reality programs, has partnered with Uvisan , a leader in rapid equipment disinfection.
  • MACE will incorporate Uvisan products into current and future clients' XR programs.
  • VR and AR were among the industries hit hardest by the pandemic, in large part due to the necessity of shared equipment in labs, training programs and arcades.
  • The result is a more hygienic environment for the trailblazers who want to leverage VR and AR safely within their organizations.

Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test

Retrieved on: 
Thursday, August 5, 2021
Company, Itch, POC, Chief executive officer, FSE, OTC Markets Group, Patent, Inflammation, Technology, United States, Machine learning, IOT, Severe acute respiratory syndrome, Partnership, Lineage B.1.1.7, Airport, Coronavirus, Apple, Intelligence, Delta, COVID-19, Twitter, School, Pain, Restaurant, Food and Drug Administration, Netflix, Work, Platform, Spokane Public Facilities District, Novel coronavirus, Naxos Island National Airport, Hospital, Education, Microsoft, Vaccine, Pharmaceutical industry

Company To Begin Embedding Solution Onto Each 15-Minute COVID-19 Rapid Antigen Test Cartridge

Key Points: 
  • Following the FDA-EUA approval for point-of-care use, this first-of-its-kind, the smart-enabled AcuVid saliva test will be submitted for FDA-EUA approval for at-home use.
  • "The AcuVid COVID-19 Rapid Antigen Saliva Test, powered by Afero, has always had the main goal of helping communities safely and securely stay open or re-open during this COVID-19 pandemic," shared Joe Britt, CEO of Afero.
  • In July 2021, Therma Bright announced that it had completed its clinical trials of its AcuVid COVID-19 Rapid Antigen Saliva Test for the successful detection of the Novel Coronavirus SARS CoV-2.
  • Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

TOMI Environmental Introduces The SteraPak – The Most Portable SteraMist System

Retrieved on: 
Wednesday, August 4, 2021
Chemical substances, Physical sciences, Materials, Disinfectants, Peroxides, Antiseptics, Hair coloring, Hydrogen peroxide, Hydrogen vehicle, Plasma, Backlog

Over the last year TOMI has utilized its patented ionized Hydrogen Peroxide (iHP) cold plasma technology platform to develop the newest SteraMist product the SteraPak.

Key Points: 
  • Over the last year TOMI has utilized its patented ionized Hydrogen Peroxide (iHP) cold plasma technology platform to develop the newest SteraMist product the SteraPak.
  • The all-in-one SteraPak, which has passed rigorous testing, places powerful, innovative SteraMist iHP technology onto your back, creating the most mobile SteraMist unit available on the market.
  • The lightweight SteraPak also features cordless as well as AC and DC power functionality which ensures compatibility in all countries.
  • TOMI is currently taking deposits from customers for the product and expects to begin filling backlog orders in the third quarter.

Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model

Retrieved on: 
Wednesday, August 4, 2021
Coronaviridae, Sarbecovirus, Zoonoses, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome, Variants of SARS-CoV-2

Based on this screening effort, the most efficacious derivative (Salicyn-30) was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection.

Key Points: 
  • Based on this screening effort, the most efficacious derivative (Salicyn-30) was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection.
  • This analysis demonstrated that Salicyn-30 can potentially reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in COVID-19 infections.
  • Moreover, based on their mechanism of action, Salicyn-30 and other lead compounds may be equally effective against recent emerging SARS-CoV-2 variants.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

AMI Partners with LifeSign To Provide the Status COVID-19/Flu A&B Test for Upcoming Respiratory Season

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Coronaviridae, Clinical medicine, Medical tests, Medical terminology, Nasopharyngeal swab, Respiratory therapy, Rapid diagnostic test, COVID-19, Severe acute respiratory syndrome, DiaSorin, Curative

Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.

Key Points: 
  • Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.
  • said Samatha Young, Head of Global Sales at AMI .
  • The LifeSign Status COVID-19 Flu A&B rapid test is a qualitative assay for the simultaneous detection of influenza A&B antigen and SARS CoV-2 antigen from nasopharyngeal swabs obtained from patients/Flu rapid combo test on the market.
  • As a leader in rapid diagnostics, LifeSign is excited and proud to partner with AMI.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.